MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – Research analysts at HC Wainwright issued their Q3 2026 EPS estimates for MiNK Therapeutics in a research report issued on Wednesday, November 4th. HC Wainwright analyst M. Keller expects that the company will earn ($0.67) per share for the quarter. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.58) EPS.
Other equities analysts have also issued research reports about the company. B. Riley Financial reissued a “buy” rating and issued a $50.00 price objective (up from $43.00) on shares of MiNK Therapeutics in a research note on Wednesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Finally, Zacks Research cut MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $44.00.
Get Our Latest Stock Report on MiNK Therapeutics
MiNK Therapeutics Price Performance
NASDAQ INKT opened at $9.94 on Friday. The stock’s 50 day simple moving average is $11.26 and its 200 day simple moving average is $11.27. MiNK Therapeutics has a one year low of $8.48 and a one year high of $16.93. The firm has a market cap of $50.72 million, a PE ratio of -4.14 and a beta of 0.49.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02).
Insider Transactions at MiNK Therapeutics
In other MiNK Therapeutics news, CEO Jennifer Buell sold 6,938 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $10.56, for a total value of $73,265.28. Following the transaction, the chief executive officer directly owned 74,195 shares in the company, valued at approximately $783,499.20. This trade represents a 8.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 20.40% of the company’s stock.
About MiNK Therapeutics
MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.
MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.
Featured Articles
- Five stocks we like better than MiNK Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
